Rouge Therapeutics secures $58 million in Series A financing co-led by Angelini Ventures and EIB to advance treatment for hereditary hemorrhagic telangiectasia.
Angelini Ventures and the European Investment Bank co-led a $58 million Series A financing in Rouge Therapeutics. The funds will support the development of RTX-001 for hereditary hemorrhagic telangiectasia, a common inherited bleeding disorder. Other participating investors included BioGeneration Ventures, Kurma Partners, and several others. This is the fourth investment made under their co-investment partnership in less than a year.
Company Information
Company
Rouge Therapeutics
Location
Rome, Lazio, Italy
About
Rouge Tx is a spin-off from Leiden University Medical Center (LUMC) focused on developing first-in-class small-molecule therapies to restore vascular stability in diseases driven by pericyte dysfunction. Their lead program targets Hereditary Hemorrhagic Telangiectasia (HHT) along with additional indications related to vascular stability diseases. The company aims to move beyond current symptom management toward urgently needed disease-modifying treatments.
Fundz sees it the moment Rouge Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
RomeBiotechnologyHealth CareMedicalTherapeutics